Trial
NCT03901469
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Zenith Epigenetics
Collaborators
Pfizer; Newsoara Biopharma Co., Ltd.
Condition
Triple Negative Breast Cancer
Intervention
ZEN003694
Why stopped
Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-07